Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation

Open access
Hashimoto, Daigo, Chow, Andrew, Greter, Melanie, Saenger, Yvonne, Kwan, Wing-Hong, Leboeuf, Marylene, Ginhoux, Florent, Ochando, Jordi C., Kunisaki, Yuya, van Rooijen, Nico, Liu, Chen, Teshima, Takanori, Heeger, Peter S., Stanley, E. Richard, Frenette, Paul S., Merad, Miriam·2011·Journal of Experimental Medicine

Abstract

Acute graft-versus-host disease (GVHD) results from the attack of host tissues by donor allogeneic T cells and is the most serious limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Host antigen-presenting cells are thought to control the priming of alloreactive T cells and the induction of acute GVHD after allo-HCT. However, whereas the role of host DC in GVHD has been established, the contribution of host macrophages to GVHD has not been clearly addressed. We show that, in contrast to DC, reducing of the host macrophage pool in recipient mice increased donor T cell expansion and aggravated GVHD mortality after allo-HCT. We also show that host macrophages that persist after allo-HCT engulf donor allogeneic T cells and inhibit their proliferation. Conversely, administration of the cytokine CSF-1 before transplant expanded the host macrophage pool, reduced donor T cell expansion, and improved GVHD morbidity and mortality after allo-HCT. This study establishes the unexpected key role of host macrophages in inhibiting GVHD and identifies CSF-1 as a potential prophylactic therapy to limit acute GVHD after allo-HCT in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20101709

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 174

Metadata

Authors
Hashimoto, D., Chow, A., Greter, M., Saenger, Y., Kwan, W.-H., Leboeuf, M., Ginhoux, F., Ochando, J. C., Kunisaki, Y., van Rooijen, N., Liu, C., Teshima, T., Heeger, P. S., Stanley, E. R., Frenette, P. S., & Merad, M.
Venue
Journal of Experimental Medicine
Published
2011-05-02
Volume
208
Issue
5
Pages
1069-1082
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2162786037
Cited by
174
References
5
FWCI
9.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. https://app.cochat.ai/papers/10.1084/jem.20101709
The paper
Hashimoto, D., Chow, A., Greter, M., Saenger, Y., Kwan, W.-H., Leboeuf, M., Ginhoux, F., Ochando, J. C., Kunisaki, Y., van Rooijen, N., Liu, C., Teshima, T., Heeger, P. S., Stanley, E. R., Frenette, P. S., & Merad, M. (2011). Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20101709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.